Zunsemetinib

Zunsemetinib (ATI-450;CDD450) is an orally active and selective p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor.


Cat. No.: EX-A6292	Purity: >98%

	Chemical structure of Zunsemetinib

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
25mg	427	in_stock
50mg	573	in_stock
100mg	879	in_stock
250mg	1267	in_stock
500mg	1861	in_stock
1g	2673	in_stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


Synonyms	ATI-450
Synonyms 2	(P)-ATI-450
CAS No.	1640282-42-3
Purity	>98%
Formula	C25H22ClF2N5O3
Mol Weight	513.924
Color	White to yellow
State	solid powder
Solubility	Soluble in DMSO 100 mg/mL
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Zunsemetinib (ATI-450) – Investigational oral MK2 pathway inhibitor [2]. Aclaris Therapeutics Announces ATI-450 (MK2 pathway Inhibitor) publication in Journal of Experimental Medicine [3]. Wang C, et al. Selective inhibition of the p38α MAPK-MK2 axis inhibits inflammatory cues including inflammasome priming signals. J Exp Med. 2018;215(5):1315-1325.
CoA	CoA of Zunsemetinib

Smiles:	FC1=CC(F)=CN=C1COC2=C(Cl)C(N(C3=CC(C4=NC(C(C)(C)O)=NC=C4)=NC=C3C)C(C)=C2)=O


		Search